Evidence & concentration worksheet · Brain Health & Nootropics
Selank 10 mg
evidence.protocol.withhold-unverified.text
Evidence review
evidence.protocol.withhold-unverified.title
evidence.protocol.withhold-unverified.text
How it works
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed and studied primarily in Russia for anxiety-related conditions. FDA’s substance database records the chemical identity but explicitly warns that a UNII identifier does not imply regulatory review or approval.[1]
No Selank product is FDA-approved in the United States. Foreign use and a chemical identifier do not validate a U.S. compounded nasal spray, injectable vial, or online research product.
Benefits & side effects
A Russian comparative study enrolled 62 patients with generalized anxiety disorder or neurasthenia and compared Selank in 30 participants with medazepam in 32, reporting similar anxiolytic effects.[2] Another Russian comparative study enrolled 60 patients with phobic-anxiety or somatoform disorders and reported benefit relative to phenazepam.[3]
These reports provide a human signal, but their small size, limited accessible methods, active comparators rather than a clearly described placebo framework, regional publication, and lack of independent large replication prevent a reliable estimate of efficacy. They do not establish cognitive enhancement, stress resilience, depression treatment, neuroprotection, or benefit in healthy people.
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- U.S. FDA GSRS — Selank substance identity record and regulatory disclaimer (2026)
- Zhurnal Nevrologii i Psikhiatrii — Selank compared with medazepam in 62 patients (2008)
- Zhurnal Nevrologii i Psikhiatrii — Selank compared with phenazepam in 60 patients (2014)
- U.S. FDA — Certain bulk substances that may present significant compounding safety risks (2026)
- U.S. FDA — September 2024 update to 503A nominated bulk-substance categories (2024)
- U.S. FDA — Understanding the risks of compounded drugs (2026)
Other vial sizes